학술논문
CML-593 The Novel BCR::ABL1 Allosteric Inhibitor HS-10382/TERN-701 is Potent Against Mutations Resistant to Active Site Tyrosine Kinase Inhibitors (TKIs) and Acts Synergistically With TKIs in BCR::ABL1+ Cancer Cell Lines
Document Type
Abstract
Author
Source
In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 1:S350-S350
Subject
Language
ISSN
2152-2650